Effect of Hepatic Impairment on LDK378 Pharmacokinetics
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
Pharmacokinetics and safety of 750 mg of LDK378 given once orally in subjects with impaired
hepatic function and healthy subjects with normal hepatic function.